Browse SCP2

Summary
SymbolSCP2
Namesterol carrier protein 2
Aliases NLTP; NSL-TP; SCP-CHI; SCP-X; SCPX; propanoyl-CoA C-acyltransferase; sterol carrier protein X; Non-specific ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Mitochondrion Note=Cytoplasmic in the liver and also associated with mitochondria especially in steroidogenic tissues.; SUBCELLULAR LOCATION: Isoform SCPx: Peroxisome. Note=Interaction with PEX5 is essential for peroxisomal import.; SUBCELLULAR LOCATION: Isoform SCP2: Mitochondrion
Domain PF02036 SCP-2 sterol transfer family
PF02803 Thiolase
PF00108 Thiolase
Function

Mediates in vitro the transfer of all common phospholipids, cholesterol and gangliosides between membranes. May play a role in regulating steroidogenesis.

> Gene Ontology
 
Biological Process GO:0001676 long-chain fatty acid metabolic process
GO:0006631 fatty acid metabolic process
GO:0006635 fatty acid beta-oxidation
GO:0006694 steroid biosynthetic process
GO:0006699 bile acid biosynthetic process
GO:0006869 lipid transport
GO:0007031 peroxisome organization
GO:0008202 steroid metabolic process
GO:0008206 bile acid metabolic process
GO:0009062 fatty acid catabolic process
GO:0010876 lipid localization
GO:0015850 organic hydroxy compound transport
GO:0015918 sterol transport
GO:0016042 lipid catabolic process
GO:0016053 organic acid biosynthetic process
GO:0016054 organic acid catabolic process
GO:0019395 fatty acid oxidation
GO:0030258 lipid modification
GO:0030301 cholesterol transport
GO:0032365 intracellular lipid transport
GO:0032366 intracellular sterol transport
GO:0032367 intracellular cholesterol transport
GO:0032368 regulation of lipid transport
GO:0032370 positive regulation of lipid transport
GO:0032371 regulation of sterol transport
GO:0032373 positive regulation of sterol transport
GO:0032374 regulation of cholesterol transport
GO:0032376 positive regulation of cholesterol transport
GO:0032377 regulation of intracellular lipid transport
GO:0032379 positive regulation of intracellular lipid transport
GO:0032380 regulation of intracellular sterol transport
GO:0032382 positive regulation of intracellular sterol transport
GO:0032383 regulation of intracellular cholesterol transport
GO:0032385 positive regulation of intracellular cholesterol transport
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0033540 fatty acid beta-oxidation using acyl-CoA oxidase
GO:0034440 lipid oxidation
GO:0036109 alpha-linolenic acid metabolic process
GO:0044242 cellular lipid catabolic process
GO:0044282 small molecule catabolic process
GO:0044283 small molecule biosynthetic process
GO:0046394 carboxylic acid biosynthetic process
GO:0046395 carboxylic acid catabolic process
GO:0072329 monocarboxylic acid catabolic process
GO:0072330 monocarboxylic acid biosynthetic process
GO:1901373 lipid hydroperoxide transport
Molecular Function GO:0000062 fatty-acyl-CoA binding
GO:0005319 lipid transporter activity
GO:0005496 steroid binding
GO:0005504 fatty acid binding
GO:0015248 sterol transporter activity
GO:0015485 cholesterol binding
GO:0016408 C-acyltransferase activity
GO:0016746 transferase activity, transferring acyl groups
GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups
GO:0031406 carboxylic acid binding
GO:0032934 sterol binding
GO:0033293 monocarboxylic acid binding
GO:0033814 propanoyl-CoA C-acyltransferase activity
GO:0036041 long-chain fatty acid binding
GO:0036042 long-chain fatty acyl-CoA binding
GO:0043168 anion binding
GO:0043178 alcohol binding
GO:0048037 cofactor binding
GO:0050632 propionyl-CoA C2-trimethyltridecanoyltransferase activity
GO:0050662 coenzyme binding
GO:0070538 oleic acid binding
GO:1901681 sulfur compound binding
Cellular Component GO:0005777 peroxisome
GO:0005782 peroxisomal matrix
GO:0031907 microbody lumen
GO:0042579 microbody
GO:0044438 microbody part
GO:0044439 peroxisomal part
> KEGG and Reactome Pathway
 
KEGG hsa03320 PPAR signaling pathway
hsa04146 Peroxisome
hsa00120 Primary bile acid biosynthesis
hsa01100 Metabolic pathways
Reactome R-HSA-389887: Beta-oxidation of pristanoyl-CoA
R-HSA-194068: Bile acid and bile salt metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-390918: Peroxisomal lipid metabolism
R-HSA-192105: Synthesis of bile acids and bile salts
R-HSA-193368: Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
R-HSA-2046104: alpha-linolenic (omega3) and linoleic (omega6) acid metabolism
R-HSA-2046106: alpha-linolenic acid (ALA) metabolism
Summary
SymbolSCP2
Namesterol carrier protein 2
Aliases NLTP; NSL-TP; SCP-CHI; SCP-X; SCPX; propanoyl-CoA C-acyltransferase; sterol carrier protein X; Non-specific ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SCP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSCP2
Namesterol carrier protein 2
Aliases NLTP; NSL-TP; SCP-CHI; SCP-X; SCPX; propanoyl-CoA C-acyltransferase; sterol carrier protein X; Non-specific ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SCP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSCP2
Namesterol carrier protein 2
Aliases NLTP; NSL-TP; SCP-CHI; SCP-X; SCPX; propanoyl-CoA C-acyltransferase; sterol carrier protein X; Non-specific ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SCP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4680.0693
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3990.892
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5270.795
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1290.66
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1860.918
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0550.98
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0520.906
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0080.997
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.20.929
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2190.918
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0820.98
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0830.294
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SCP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.81.413.40.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.81.713.10.032
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSCP2
Namesterol carrier protein 2
Aliases NLTP; NSL-TP; SCP-CHI; SCP-X; SCPX; propanoyl-CoA C-acyltransferase; sterol carrier protein X; Non-specific ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SCP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSCP2
Namesterol carrier protein 2
Aliases NLTP; NSL-TP; SCP-CHI; SCP-X; SCPX; propanoyl-CoA C-acyltransferase; sterol carrier protein X; Non-specific ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SCP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SCP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSCP2
Namesterol carrier protein 2
Aliases NLTP; NSL-TP; SCP-CHI; SCP-X; SCPX; propanoyl-CoA C-acyltransferase; sterol carrier protein X; Non-specific ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SCP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSCP2
Namesterol carrier protein 2
Aliases NLTP; NSL-TP; SCP-CHI; SCP-X; SCPX; propanoyl-CoA C-acyltransferase; sterol carrier protein X; Non-specific ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SCP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSCP2
Namesterol carrier protein 2
Aliases NLTP; NSL-TP; SCP-CHI; SCP-X; SCPX; propanoyl-CoA C-acyltransferase; sterol carrier protein X; Non-specific ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SCP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSCP2
Namesterol carrier protein 2
Aliases NLTP; NSL-TP; SCP-CHI; SCP-X; SCPX; propanoyl-CoA C-acyltransferase; sterol carrier protein X; Non-specific ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SCP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.